Welcome to our dedicated page for Gilead Sciences news (Ticker: GILD), a resource for investors and traders seeking the latest updates and insights on Gilead Sciences stock.
Gilead Sciences, Inc. is an American biopharmaceutical company based in Foster City, California. The company specializes in researching, developing, and marketing antiviral drugs used in the treatment of a variety of viral infections including HIV/AIDS, hepatitis B and C, influenza, and COVID-19. Gilead is renowned for its innovative approach to creating life-saving therapies, with a core focus on diseases such as HIV and hepatitis. Some of its groundbreaking products include ledipasvir/sofosbuvir and sofosbuvir, pivotal in the treatment of hepatitis C.
Gilead's extensive portfolio has been significantly enhanced through strategic acquisitions. The purchase of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga has allowed the company to diversify into pulmonary and cardiovascular diseases and cancer treatments. The acquisition of Pharmasset was particularly notable, providing Gilead with the rights to the hepatitis C drug Sovaldi, further combined into the drug Harvoni. Additionally, Gilead has expanded its oncology offerings through the acquisitions of Kite, Forty Seven, and Immunomedics, strengthening its position in both cell therapy and non-cell therapy in oncology.
Gilead continually seeks to innovate and push the boundaries of medicine to offer better therapeutic solutions. Recent projects include expanding its antiviral pipeline and exploring novel treatments for various cancers. Financially, Gilead remains robust, with substantial investments in research and development to drive future growth and maintain its leadership in the biopharmaceutical industry.
Rhea-AI Summary
Gilead Sciences, Inc. (Nasdaq: GILD) has announced a 2.7% increase in the company’s quarterly cash dividend, starting in the first quarter of 2024. The dividend will amount to $0.77 per share of common stock and will be payable on March 28, 2024, to stockholders of record as of March 15, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.25%
Tags
-
Rhea-AI Summary
Gilead Sciences, Inc. reported a 7% increase in product sales excluding Veklury, 14% increase in Biktarvy sales, and a 37% increase in oncology sales for the full year 2023. However, total revenue decreased by 4% in the fourth quarter of 2023 compared to the same period in 2022. The company's diluted EPS decreased to $1.14 in the fourth quarter of 2023. Gilead had $8.4 billion of cash, cash equivalents, and marketable debt securities as of December 31, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.25%
Tags
-
Rhea-AI Summary
Gilead Sciences has been named one of Newsweek America's Greatest Workplaces for Diversity. The company is a research-based biopharmaceutical company that discovers, develops, and commercializes innovative medicines in areas of unmet medical need. Gilead operates in more than 35 countries worldwide and has headquarters in Foster City, California.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.32%
Tags
Rhea-AI Summary
Gilead Sciences, Inc. (Nasdaq: GILD) appoints Dr. Ted Love, a highly respected executive leader in the biopharma industry, to its Board of Directors. Dr. Love has extensive experience and a strong scientific background, having led a pre-clinical startup to a global commercial company with a focus on sickle cell disease. He is known for championing access to care and has received distinguished service awards for addressing healthcare disparities. Gilead's Chairman and CEO, Daniel O’Day, expressed delight in welcoming Dr. Love to the board, citing his alignment with Gilead's values and his potential to contribute to the company's impact on patients and communities worldwide.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.54%
Tags
-
Rhea-AI Summary
Kite, a Gilead Company, has received FDA approval for a manufacturing process change that will reduce the turnaround time for Yescarta from 16 days to 14 days. This change is crucial for patients with relapsed or refractory large B-cell lymphoma, as it allows for a quicker delivery of the CAR T-cell therapy, potentially improving the patients' chances of survival. The approval is expected to benefit healthcare providers and patients, with Kite's focus on increasing manufacturing capacity and reliability.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.57%
Tags
-
Rhea-AI Summary
Gilead Sciences released a new book called 'From the Margins' featuring the personal journeys of six people in the UK living with HIV, hepatitis C, and cancer. The book aims to raise awareness about the challenges faced due to stigma and health inequities. Each person's experience is deliberately written around the margins of the book to depict what it feels like to live on the periphery of society with a chronic or life-threatening disease.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.57%
Tags
Rhea-AI Summary
Gilead Sciences, Inc. and Arcus Biosciences, Inc. have announced an amendment to their collaboration agreement and a separate equity investment by Gilead of $320 million in Arcus common stock at $21.00 per share. The investment reinforces the companies' conviction in the TIGIT pathway and provides an opportunity to accelerate the anti-TIGIT program. The amendment also provides Gilead with one additional seat on the Arcus Board. The press release highlights the governance enhancements enabling streamlined decision-making and reflects the continued growth of the collaboration. Gilead and Arcus have reprioritized the joint domvanalimab development program to focus on advancing and potentially accelerating the Phase 3 studies STAR-121 (lung cancer) and STAR-221 (gastrointestinal cancer). This prioritization reflects the companies' continued conviction in the TIGIT pathway and the Fc-silent design of domvanalimab, which has the potential for differentiation in both efficacy and safety. The additional investment by Gilead, which extends Arcus' cash runway into 2027, will enable the funding of Phase 3 studies of quemliclustat in pancreatic cancer and AB521 in kidney cancer, as well as the preparation for potential product approvals.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.57%
Tags
-
Rhea-AI Summary
Gilead Sciences, Inc. invests $320 million in Arcus Biosciences, Inc. and amends collaboration agreement, raising Gilead's ownership stake in Arcus to 33%. The investment aims to accelerate the joint development programs, with a focus on advancing Phase 3 studies for lung and gastrointestinal cancers. The amendment also provides Gilead with one additional seat on the Arcus Board, enabling streamlined decision-making.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.57%
Tags
-
Rhea-AI Summary
Gilead Sciences, Inc. (GILD) will release its Q4 and full year 2023 financial results and guidance on February 6, 2024. A webcast will be hosted by the company's management to discuss the results and provide a business update.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.06%
Tags
Rhea-AI Summary
The press release discusses the partnership between Gilead and the Metastatic Breast Cancer Association to use artificial intelligence to share the experiences of women living with metastatic triple-negative breast cancer (mTNBC). The collaboration resulted in the creation of unique paintings that depict the emotional weight of living with this diagnosis. The project, Paintings of Hope, received numerous honors and was displayed in hospitals around Spain, as well as in the Spanish Parliament. The success of this project led to the launch of a new project, Portraits of Hope, which takes a more personal approach with the involvement of well-known Spanish artists.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.34%
Tags
FAQ
What is the current stock price of Gilead Sciences (GILD)?
The current stock price of Gilead Sciences (GILD) is $90.19 as of November 22, 2024.
What is the market cap of Gilead Sciences (GILD)?
The market cap of Gilead Sciences (GILD) is approximately 111.8B.
What is Gilead Sciences, Inc.?
Gilead Sciences is an American biopharmaceutical company that focuses on developing antiviral drugs for diseases like HIV, hepatitis B and C, influenza, and COVID-19.
Where is Gilead Sciences headquartered?
Gilead Sciences is headquartered in Foster City, California.
What are some key products of Gilead Sciences?
Some key products include ledipasvir/sofosbuvir and sofosbuvir for hepatitis C treatment and several innovative antiviral therapies.
Which companies has Gilead Sciences acquired?
Gilead has acquired companies such as Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, Calistoga, Pharmasset, Kite, Forty Seven, and Immunomedics.
What diseases does Gilead Sciences' portfolio cover?
Gilead's portfolio covers life-threatening diseases like HIV, hepatitis B and C, pulmonary and cardiovascular diseases, influenza, and various cancers.
How has Gilead expanded its oncology offerings?
Gilead has bolstered its oncology portfolio through acquisitions of Kite, Forty Seven, and Immunomedics, enhancing its cell therapy and non-cell therapy options.
What is Gilead's financial condition?
Gilead maintains a strong financial position with significant investments in research and development to support ongoing growth and innovation.
What is Gilead's approach to research and development?
Gilead focuses on continual innovation and investment in R&D to develop groundbreaking treatments for viral infections and other serious diseases.
What recent projects is Gilead working on?
Gilead is currently working on expanding its antiviral drug pipeline and exploring new treatments for various types of cancer.
Where can I find the latest news about Gilead Sciences?
You can find the latest updates and news about Gilead Sciences on their official website and through reliable financial news sources.
Gilead Sciences Inc
Nasdaq:GILD
GILD Rankings
GILD Stock Data
111.79B
1.24B
0.12%
88.41%
1.42%
Drug Manufacturers - General
Biological Products, (no Disgnostic Substances)
United States of America
FOSTER CITY